Results 241 to 250 of about 5,108,464 (344)

New approaches in radiotherapy for treatment of advanced ovarian cancer

open access: bronze, 1987
William R. Redwood   +2 more
openalex   +1 more source

Mechanisms and modulation of resistance to chemotherapy in ovarian cancer [PDF]

open access: bronze, 1993
Raymond P. Perez   +3 more
openalex   +1 more source

eIF4E Enriched Extracellular Vesicles Induce Immunosuppressive Macrophages through HMGCR‐Mediated Metabolic Rewiring

open access: yesAdvanced Science, EarlyView.
Here, it is revealed that ovarian cancer cells release extracellular vesicles enriched with eIF4E, which alters protein production in macrophages. This leads to increased expression of 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase (HMGCR), boosting cholesterol synthesis and activating an immunosuppressive pathway through X‐box binding protein 1 and ...
Sonam Mittal   +15 more
wiley   +1 more source

Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model

open access: green, 1994
Barbara A. Goff   +5 more
openalex   +1 more source

Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. [PDF]

open access: bronze, 1994
Ichiro Yoshino   +4 more
openalex   +1 more source

Disruption of Gut Microbiota‐Mediated De Novo NAD+ Synthesis Contributes to the Development of Polycystic Ovary Syndrome

open access: yesAdvanced Science, EarlyView.
This study demonstrates that patients with PCOS exhibit altered gut microbial profiles, and FMT from PCOS patients induces PCOS‐like symptoms in mice. Specifically, gut dysbiosis reduces 3‐HAA levels in the context of PCOS. Administration of 3‐HAA to mice alleviates PCOS by promoting de novo NAD+ synthesis.
Ke Chen   +6 more
wiley   +1 more source

Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy

open access: bronze, 1994
CJ Jr Link   +7 more
openalex   +1 more source

Lenvatinib Plus Paclitaxel as Second‐Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study

open access: yesAdvanced Science, EarlyView.
This study determines the maximum tolerated dose of lenvatinib in combination with paclitaxel as second‐line therapy for advanced gastric cancer patients. A dynamic network biomarker panel associated with patient prognosis and response to treatment is established.
Chenfei Zhou   +8 more
wiley   +1 more source

Detection of p53 Gene Mutations in Human Ovarian and Endometrial Cancers by Polymerase Chain Reaction‐Single Strand Conformation Polymorphism Analysis [PDF]

open access: green, 1992
Mariko Fujimoto Naito   +7 more
openalex   +1 more source

ACSS2/AATF Drives Soluble FasL‐Mediated CD8+ T Cell Apoptosis in Pancreatic Neuroendocrine Tumors

open access: yesAdvanced Science, EarlyView.
This study unveils that ACSS2‐driven acetate metabolism fuels histone pan‐acetylation in pancreatic neuroendocrine tumors (PNETs), remodeling the epigenetic landscape. The ACSS2/AATF axis transcriptionally activates soluble FasL (sFasL), which engages Fas receptors on infiltrating CD8+ T cells to trigger caspase‐8/3‐mediated apoptosis.
Qin Dang   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy